{
    "eid": "2-s2.0-85092010260",
    "title": "Augmentation of NK Cell Proliferation and Anti-tumor Immunity by Transgenic Expression of Receptors for EPO or TPO",
    "cover-date": "2021-01-06",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Molecular Biology",
            "@code": "1312",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Genetics",
            "@code": "1311",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "c-MPL",
        "cellular immunotherapy",
        "EPO",
        "EPOR",
        "erythropoietin",
        "MPL",
        "natural killer cell",
        "THPO",
        "thrombopoietin",
        "TPO"
    ],
    "authors": [
        "Chantiya Chanswangphuwana",
        "David S.J. Allan",
        "Mala Chakraborty",
        "Robert N. Reger",
        "Richard W. Childs"
    ],
    "citedby-count": 9,
    "ref-count": 49,
    "ref-list": [
        "NK cell-based immunotherapy for cancer",
        "Expanded and armed natural killer cells for cancer treatment",
        "Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens",
        "Engineering Natural Killer Cells for Cancer Immunotherapy",
        "Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications",
        "IL-15 signaling in NK cell cancer immunotherapy",
        "The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells",
        "Guidelines for the safe administration of high-dose interleukin-2",
        "Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer",
        "Effects of route and formulation on clinical pharmacokinetics of interleukin-2",
        "Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo",
        "Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells",
        "Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy",
        "Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor",
        "Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15",
        "Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity",
        "Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor \u03b1Su/Fc fusion complex in syngeneic murine models of multiple myeloma",
        "First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation",
        "Erythropoiesis-stimulating agents for anemic patients with cancer",
        "Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists",
        "The erythropoietin receptor in normal and cancer tissues",
        "Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin",
        "Thrombopoietin from beginning to end",
        "The IL-2 cytokine family in cancer immunotherapy",
        "c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals",
        "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation",
        "Distinct downstream signaling mechanism between erythropoietin receptor and interleukin-2 receptor",
        "Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors",
        "Genome-wide analyses and functional profiling of human NK cell lines",
        "First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia",
        "Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial",
        "Treatment of patients with advanced cancer with the natural killer cell line NK-92",
        "A novel mechanism of cooperation between c-Kit and erythropoietin receptor. Stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin",
        "Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways",
        "Highly efficient IL-21 and feeder cell-driven ex vivo expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma",
        "Immunometabolism and natural killer cell responses",
        "Metabolic Reprogramming Supports IFN-\u03b3 Production by CD56bright NK Cells",
        "Mechanisms of L-selectin regulation by activated T cells",
        "An essential role for ectodomain shedding in mammalian development",
        "IL-21 Selectively Protects CD62L+NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy",
        "CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells",
        "L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration",
        "Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X",
        "Immunosuppressive effects of erythropoietin on human alloreactive T cells",
        "Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist",
        "Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand",
        "Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist",
        "Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells",
        "An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bethesda",
            "@id": "60005281",
            "affilname": "National Heart, Lung, and Blood Institute (NHLBI)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005281",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "John Tisdale",
        "Joseph Clara",
        "Keyvan Keyvanfar",
        "Naoya Uchida",
        "US Public Health Service",
        "NIH",
        "NHLBI",
        "US Public Health Service",
        "Chulalongkorn University"
    ]
}